| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00005776021 |
| 005 |
20260327191509.0 |
| 006 |
m o d |
| 007 |
cr cnu|||||||| |
| 008 |
230619s2023 ne a ob 001 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OCLCO
|d OCLCQ
|
| 020 |
|
|
|a 9780323917711
|
| 020 |
|
|
|a 0323917712
|
| 035 |
|
|
|a (OCoLC)1535408076
|
| 050 |
|
4 |
|a RB131
|b .L385 2023
|
| 082 |
0 |
4 |
|a 616.0473
|2 23
|
| 049 |
|
|
|a TXAM
|
| 100 |
1 |
|
|a Laule, Cornelia,
|e author.
|
| 245 |
1 |
0 |
|a Imaging neuroinflammation /
|c Cornelia Laule.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Amsterdam, Netherlands :
|b Academic press,
|c [2023]
|
| 264 |
|
4 |
|c ©2023
|
| 300 |
|
|
|a 1 online resource (514 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in magnetic resonance technology and applications ;
|v 9
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Intro -- Imaging Neuroinflammation -- Copyright -- Contents -- List of contributors -- Preface -- Part 1: Overview -- Chapter 1: Molecular and tissue basis of neuroinflammation in health and disease -- General introduction -- Peripheral inflammation -- The case of neuroinflammation -- Blood-brain barrier alterations -- Increased blood-brain barrier permeability induced by inflammation -- Pathological substrate -- Introduction to BBB permeability-associated imaging biomarkers -- Entrance of inflammatory cells across the inflamed blood-brain barrier -- Pathological substrate -- Introduction to immune cell infiltration-associated imaging biomarkers -- Edematous component associated with inflammation -- Pathological substrate -- Introduction to edema-associated imaging biomarkers -- Inflammatory activation of microglia and astrocytes -- Pathological substrate -- Introduction to microglia and astrocyte-associated imaging biomarkers -- Inflammatory attack on myelin -- Pathological substrate -- Introduction to myelin-associated imaging biomarkers -- Neuronal injury -- Pathological substrate -- Introduction to neuronal-associated imaging biomarkers -- Iron -- Pathological substrate -- Introduction to iron-associated imaging biomarkers -- Conclusion -- References -- Part 2: Imaging approaches to inflammation -- Chapter 2: Sensitivity and specificity of diffusion MRI to neuroinflammatory processes -- What is diffusion MRI? -- Sensitivity of diffusion MRI to cellular inflammatory processes -- Diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) -- Sensitivity of DTI and DKI to neuroinflammation -- Animal validation studies showing sensitivity of diffusion MRI to neuroinflammation -- Human studies of neuroinflammation using DTI and DKI -- Specificity of diffusion MRI to cellular inflammatory processes.
|
| 505 |
8 |
|
|a Overview of popular diffusion MRI models -- Models applied to animal studies of neuroinflammation -- Models applied to human studies involving neuroinflammation -- Conclusion and outlook -- References -- Chapter 3: Iron imaging in neuroinflammation -- Introduction -- Iron and neuroinflammation -- Imaging iron in neuroinflammation -- Magnitude techniques and relaxation time measurements -- T2 -- T2* -- Phase-based iron imaging -- Susceptibility-weighted imaging (SWI) -- Susceptibility-based iron quantification -- Phase processing -- Quantitative susceptibility mapping (QSM) -- Susceptibility source separation -- Miscellaneous considerations -- Iron oxide particles -- Field strength relevance -- Conclusions -- Acknowledgments -- References -- Chapter 4: MRS in neuroinflammation -- Abbreviations -- Introduction -- Brain metabolism accessible with MRS -- Metabolites visible with MRS -- NAA -- Creatine -- Choline -- Myo-inositol -- Lactate -- Glutamate and glutamine -- Glx -- Glutathione -- Gamma-aminobutyric acid -- GABA -- 2-Hydroxyglutarate (2HG) -- Macromolecules and lipids -- Case study of MRS in neuroinflammation: Multiple sclerosis as a primary inflammatory disease -- Multiple sclerosis pathophysiology -- Metabolic changes measured by MRS in MS -- MRS data acquisition -- Basics of MRS data acquisition -- Signal localization -- Water suppression -- T1 nulling -- Chemical shift selective (CHESS) water suppression -- Variable power and optimized relaxations delays (VAPOR) -- Metabolite cycling (MC) -- Acquisition parameters -- Echo time -- Echo digitization -- Repetition time -- Voxel size and scan duration -- Spectral editing -- J-difference editing or editing -- Multinuclear MRS -- 31-Phosphorus -- 13-Carbon -- Diffusion MRS -- MRS data analysis -- Processing steps -- Processing -- Spectral fitting -- Peak modeling -- Linear combination modeling.
|
| 505 |
8 |
|
|a Tissue correction and metabolite quantification -- Water-referenced data -- Metabolite-referenced data -- Issues with metabolite quantification -- Spectral quality assurance and assessment -- Quality assurance during acquisition -- Artifacts -- Quality assessment and rejection thresholds -- Reporting standards and how to read MRS literature -- Summary -- References -- Further reading -- Chapter 5: Magnetization transfer and chemical exchange saturation transfer in neuroinflammation -- Abbreviations -- Introduction -- Central nervous system inflammation -- Magnetization transfer as an umbrella term -- MTC phenomenon and observations -- The MT experiment -- Quantification of the MT effect -- The MTR -- Quantitative MT (qMT) -- Origin of the MT effect -- MT imaging of acute inflammation: Histopathological and clinical validations -- MT imaging of chronic inflammation: Histopathological and clinical validations -- MT applications: Concluding remarks -- Chemical exchange saturation transfer -- Background -- CEST phenomenon and APT CEST -- The CEST experiment -- Quantification of CEST -- Confounds to the asymmetry measurement of the CEST effect -- Summary of confounds -- Model free CEST correction: AREX -- Model-based CEST correction: Lorentzian fitting -- CEST imaging of acute inflammation: Histopathological and clinical validations -- CEST imaging of chronic inflammation: Histopathological and clinical validations -- CEST applications: Concluding remarks -- Unmet needs and application opportunities -- Conclusion -- References -- Chapter 6: Gadolinium-based imaging of the blood brain barrier and brain waste clearance pathways -- Introduction -- Physiology and anatomy of the blood-brain barrier -- Paravascular and perivascular spaces -- Interstitial fluid -- Brain waste clearance pathways -- Glymphatic system.
|
| 505 |
8 |
|
|a Intramural periarterial drainage pathway-IPAD -- Meningeal lymphatics -- Gadolinium-based magnetic resonance imaging of brain waste clearance pathways and blood-brain barrier disruption -- Gadolinium-based contrast agents-Pharmacokinetics -- Gadolinium-based contrast agents-Signal intensity on MRI -- Intravenous injection of GBCA and in vivo MRI-based imaging -- Intrathecal injection of GBCA and in vivo MRI-based imaging -- Gadolinium-based MRI techniques and the disrupted blood-brain barrier -- Pathological conditions and clearance consequences of BBB disruption -- Conclusions -- References -- Chapter 7: Magnetic particle imaging -- In vivo cellular imaging with magnetic resonance imaging -- In vivo cellular imaging with magnetic particle imaging -- Basic principles of MPI -- Nanoparticles for MPI -- Analysis and quantification of MPI data -- MPI of inflammation -- MPI in the brain -- Challenges and limitations of MPI -- Future of MPI cell tracking -- References -- Chapter 8: Positron emission tomography imaging of neuroinflammation -- Abbreviations -- Introduction to neuroinflammation -- Biomarkers of neuroinflammation -- Microglia -- Neuroinflammatory imaging biomarkers present on the microglia -- Translocator protein (TSPO) -- Cannabinoid receptor type 2 (CB2R) -- P2X purinoceptor 7 (P2X7R) -- Colony-stimulating factor 1 receptor (CSF1R) -- Inducible nitric oxide synthase (iNOS) -- Oxidative stress -- Glycogen synthase kinase (GSK-3) -- Inflammatory cytokines -- Cyclooxygenase (COX) -- Infiltration of macrophages, neutrophils, and T-lymphocytes -- Interleukin-2 (IL-2) -- Matrix metalloproteinases 2 (MMP-2) -- Role of astrocytes -- Neuroinflammatory imaging biomarkers present on astrocytes -- Enzymes (MAOs) -- Reversible MAO-A/B binding inhibitor-based tracers -- Irreversible MAO-A/B binding inhibitors-based tracers -- Metabolite trapping approach.
|
| 505 |
8 |
|
|a Other emerging tracers -- Imidazoline-2 receptors (I2IR) -- Adenosine receptors -- Cytosolic phospholipase A2 (cPLA2) -- Conclusion -- Acknowledgment -- References -- Part 3: Animal models -- Chapter 9: The use of animal models of neuroinflammation for imaging studies -- Introduction -- Importance of preclinical models -- Applicability of preclinical models to humans -- Animal models of central nervous system neuroinflammation -- Transgenic mouse models -- Experimental autoimmune encephalomyelitis (EAE) -- Lipopolysaccharide (LPS) -- Cuprizone -- Stroke models -- Autism models -- Hypoxia -- Sex and hormone differences in animal models of CNS inflammation -- Gut microbiome-CNS axis -- Applicability and clinical relevance: Are there bad animal models of disease? -- Developing imaging methods to study CNS inflammation -- Gadolinium as a marker of neuroinflammation -- Inflammatory components for imaging consideration -- Imaging physiological, microstructural, and biochemical changes -- New horizons -- Acknowledgments -- References -- Part 4: Human inflammation-based diseases -- Chapter 10: Stroke -- Introduction -- Stroke pathophysiology -- Neuroinflammation in stroke -- Microglia -- Adhesion molecules and leukocytes -- Inflammation resolution -- The influence of systemic and neuroinflammation on stroke recovery -- Dynamic contrast enhanced imaging -- Diffusion imaging -- Magnetic resonance spectroscopy -- Positron emission tomography -- Superparamagnetic particles of iron oxide enhanced MRI -- Conclusion -- References -- Chapter 11: Central nervous system vasculitis -- Historical diagnostic approach -- Cerebrospinal fluid -- Neuroimaging -- Biopsy -- Vessel wall magnetic resonance imaging (VWMRI) -- Diagnostic features -- Technical considerations and imaging pitfalls -- Differential diagnosis -- Reversible cerebral vasoconstriction syndrome (RCVS).
|
| 500 |
|
|
|a Intracranial atherosclerosis.
|
| 520 |
|
|
|a Imaging Neuroinflammation provides an overview of the molecular and cellular basis of inflammation and its effects on neuroanatomy, reviews state-of-the-art imaging tools available to measure neuroinflammation, and describes the application of those tools to both preclinical animal disease models and human disease.This book is an authoritative.
|
| 588 |
|
|
|a Description based on print version record.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 650 |
|
0 |
|a Central nervous system
|x Imaging.
|
| 650 |
|
0 |
|a Inflammation.
|
| 650 |
|
0 |
|a Magnetic resonance imaging.
|
| 650 |
|
2 |
|a Neuroinflammatory Diseases
|x diagnostic imaging
|
| 650 |
|
2 |
|a Inflammation
|
| 650 |
|
2 |
|a Magnetic Resonance Imaging
|
| 650 |
|
6 |
|a Système nerveux central
|x Imagerie.
|
| 650 |
|
6 |
|a Inflammation (Pathologie)
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 830 |
|
0 |
|a Advances in Magnetic Resonance Technology and Applications Series.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/bookseries/26669099/9
|z Connect to the full text of this electronic book
|t 0
|
| 936 |
|
|
|a BATCHLOAD
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 245b25cb-9dc7-4267-af2a-e9576f14c51e
|s 19210945-aee2-4b5e-a30c-abb3497f3c86
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RB131 .L385 2023
|h Library of Congress classification
|
| 998 |
f |
f |
|a RB131 .L385 2023
|t 0
|l Available Online
|